COPENHAGEN, Denmark, July 07, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that we have launched our US eCommerce portal, where the US consumers, can get the trademarked skin care line Vilact® which contains Lactoactive® “the super molecule” that makes a huge different on skin issues as well as smooths, moisturize and beautifying the skin.
With this new eCommerce portal (www.vilacto.com), our products is now available all over the US helping people to get an opportunity to use an alternative to the known products that either doesn’t help or causes side effects.
"This is another important step in our evolution as a public company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive super-molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetics, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
Gert Andersen
Phone: +1 646-893-7895
About Vilacto Bio Inc’s new eCommerce portal


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Apple Turns 50: From Garage Startup to AI Crossroads
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



